State Street’s Damora Therapeutics DMRA Stock Holding History

State Street’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.2M	Buy	1,545,500 +1,361,578	+740%	+$33M	﹤0.01%	1988
2026 Q1	$4.76M	Buy	+183,922	New	+$4.73M	﹤0.01%	2981
2024 Q3	–	Sell	-1,796	Closed	-$21.3K	–	4312
2024 Q2	$21.3K	Hold	1,796	–	–	﹤0.01%	4271
2024 Q1	$35K	Hold	1,796	–	–	﹤0.01%	4215
2023 Q4	$32.3K	Hold	1,796	–	–	﹤0.01%	4273
2023 Q3	$32.3K	Hold	1,796	–	–	﹤0.01%	4369
2023 Q2	$113K	Hold	1,796	–	–	﹤0.01%	4202
2023 Q1	$89.4K	Hold	1,796	–	–	﹤0.01%	4355
2022 Q4	$51.6K	Hold	1,796	–	–	﹤0.01%	4552
2022 Q3	$85K	Hold	1,796	–	–	﹤0.01%	4518
2022 Q2	$78K	Buy	1,796 +76	+4%	+$3.49K	﹤0.01%	4613
2022 Q1	$95K	Hold	1,720	–	–	﹤0.01%	4656
2021 Q4	$130K	Hold	1,720	–	–	﹤0.01%	4510
2021 Q3	$154K	Buy	+1,720	New	+$184K	﹤0.01%	4440

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

State Street's DMRA Position: Q2 2026 in Review

State Street increased its Damora Therapeutics (DMRA) stake by 740% in Q2 2026, buying an estimated $33M and bringing the position to 1,545,500 shares worth $40.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1988.

State Street first reported a position in DMRA in Q3 2021 and has held it in 14 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

State Street held 1,545,500 shares of Damora Therapeutics worth $40.2M as of Q2 2026.
State Street bought 1,361,578 Damora Therapeutics shares in Q2 2026, an estimated $33M.
Damora Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1988 holding.
State Street first reported a position in Damora Therapeutics in Q3 2021 and has held it in 14 quarters since.
104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.